AIM
TARO

ARK Investment Management’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

ARK Investment Management’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,446
Closed -$2.14M – 199
2024
Q1 		$2.14M Sell
50,446
-4,820
-9% -$203K 0.01% 187
2023
Q4 		$2.31M Sell
55,266
-2,295
-4% -$84.6K 0.01% 163
2023
Q3 		$2.17M Sell
57,561
-24,058
-29% -$903K 0.02% 167
2023
Q2 		$3.1M Buy
81,619
+10,294
+14% +$323K 0.02% 139
2023
Q1 		$1.73M Buy
71,325
+3,413
+5% +$99.5K 0.01% 185
2022
Q4 		$1.97M Buy
67,912
+6,625
+11% +$197K 0.02% 187
2022
Q3 		$1.84M Buy
61,287
+5,347
+10% +$184K 0.01% 198
2022
Q2 		$2.05M Buy
55,940
+374
+0.7% +$14.3K 0.01% 192
2022
Q1 		$2.4M Buy
55,566
+6,307
+13% +$295K 0.01% 205
2021
Q4 		$2.47M Sell
49,259
-1,908
-4% -$107K 0.01% 229
2021
Q3 		$3.26M Sell
51,167
-25,431
-33% -$1.76M 0.01% 227
2021
Q2 		$5.51M Sell
76,598
-2,029
-3% -$149K 0.01% 217
2021
Q1 		$5.8M Buy
78,627
+50,606
+181% +$3.84M 0.01% 203
2020
Q4 		$2.06M Buy
28,021
+15,325
+121% +$985K 0.01% 176
2020
Q3 		$696K Sell
12,696
-2,418
-16% -$150K ﹤0.01% 176
2020
Q2 		$1M Buy
15,114
+8,335
+123% +$559K 0.01% 161
2020
Q1 		$415K Buy
6,779
+2,072
+44% +$154K 0.01% 143
2019
Q4 		$414K Sell
4,707
-856
-15% -$72.2K 0.01% 145
2019
Q3 		$420K Buy
5,563
+787
+16% +$63.9K 0.01% 157
2019
Q2 		$408K Sell
4,776
-210
-4% -$20.8K 0.01% 158
2019
Q1 		$539K Sell
4,986
-146
-3% -$14.5K 0.02% 121
2018
Q4 		$434K Buy
5,132
+389
+8% +$37.5K 0.02% 128
2018
Q3 		$466K Sell
4,743
-642
-12% -$69.5K 0.01% 151
2018
Q2 		$623K Sell
5,385
-46
-0.8% -$5.05K 0.02% 111
2018
Q1 		$536K Buy
5,431
+3,075
+131% +$312K 0.03% 129
2017
Q4 		$247K Buy
+2,356
New +$259K 0.02% 141

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GCM
Gladius Capital Management Chicago, Illinois $1.65B AUM 25.75% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

ARK Investment Management's TARO Position: Q2 2024 in Review

ARK Investment Management sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2024, closing a stake of 50,446 shares — an estimated $2.14M sold.

ARK Investment Management first reported a position in TARO in Q4 2017 and held it in 26 quarters. The position peaked at $5.8M in Q1 2021. 16 funds tracked by Wall St. Rank hold TARO as of Q2 2024.

  • ARK Investment Management reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2024 after selling out during the quarter.
  • ARK Investment Management sold 50,446 Taro Pharmaceutical Industries Ltd. shares in Q2 2024, an estimated $2.14M.
  • ARK Investment Management first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2017 and held it in 26 quarters.
  • ARK Investment Management's Taro Pharmaceutical Industries Ltd. position peaked at $5.8M in Q1 2021.
  • 16 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2024.

Based on ARK Investment Management's 13F filing for Q2 2024, filed 26 Jul 2024.